Clinical trials: ANCA-Associated Vasculitis
Vasculitis, Microscopic Polyangiitis
Alemtuzumab for ANCA Associated Refractory Vasculitis
Overview: This open label, randomized, multi-centre study will enroll and treat 24 patients with refractory AAV. Aims: To determine the clinical response and severe adverse event rates associated with alemtuzumab therapy among…
- Conditions
- Vasculitis, Microscopic Polyangiitis, Granulomatosis With Polyangiitis, Wegener's
- Trial name
- ALEVIATE (NCT01405807)
- Testing
- Alemtuzumab
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
Toxicity of anti-IL-5
- Conditions
- Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
- Trial name
- NCT00266565
- Testing
- Mepolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Systemic Sclerosis, Other Connective Tissue Disease
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis.
- Conditions
- Systemic Sclerosis, Other Connective Tissue Disease, Systemic Lupus Erythematosus, Dermatomyositis
- Trial name
- NETOSE (NCT06462768)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
This is a phase IV, single-center, randomized, placebo-controlled pilot study that will evaluate the efficacy of rituximab at inducing otolaryngologic remission in GPA patients with active otolaryngologic disease.
- Trial name
- RENTGPA (NCT02626845)
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hospital for Special Surgery, New York
Wegener's Granulomatosis
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Wegener's granulomatosis (WG) is a rare disease that causes inflammation of blood vessels, or vasculitis. It may involve many different parts of the body, but typically affects the upper and lower respiratory tract and kidneys.
- Trial name
- NCT00468208
- Testing
- Abatacept
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Myocarditis, ANCA Associated Vasculitis
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of…
- Conditions
- Myocarditis, ANCA Associated Vasculitis, Pericarditis, Systemic Sclerosis
- Trial name
- EACVI-INFLAME (NCT07077304)
- Testing
- observational study
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Churg Strauss Syndrome
Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome
Churg-Strauss syndrome is a rare type of systemic vasculitis which occurs almost exclusively in patients with asthma and which is characterized by prominent blood and tissue eosinophilia.
- Trial name
- MEPOCHUSS (NCT00716651)
- Testing
- mepolizumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital Schleswig-Holstein
Churg-Strauss Syndrome
Rituxan in Churg Strauss Syndrome With Renal Involvement
Churg-Strauss Syndrome (CSS) is a disease characterized by asthma, abnormally high amounts of eosinophils (a type of white blood cell), and blood vessel inflammation. About 25% of CSS patients develop kidney disease.
- Trial name
- NCT00424749
- Testing
- Rituximab, Prednisone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fernando Fervenza
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
This is an investigator-initiated trial to evaluate the safety and efficacy of anti- CD19-CAR-T cells in the relapse or refractory autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT06420154
- Testing
- anti-CD19-CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Autoimmune diseases refer to a common category of diseases caused by the immune system reacting to self-antigens, leading to tissue damage.
- Conditions
- Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome, ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06828042
- Testing
- anti-CD19 CAR T cell therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, ANCA-Associated Glomerulonephritis
Stratified Therapy on Pediatric AAGN
Clinical information of children with ANCA-associated nephritis admitted to Children's Hospital Affiliated to Chongqing Medical University and partner centers from January 1, 2023 to December 31, 2023 was collected: To evaluate…
- Trial name
- STPARS (NCT05969522)
- Testing
- GlucoCorticoid
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wang Mo
Vasculitis
Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Treatment of patients with PR3-ANCA-associated vasculitis consists of two phases: remission induction with highly effective, but also relatively toxic, drugs and, secondly, after remission is achieved, maintenance therapy with…
- Trial name
- NCT00128895
- Testing
- azathioprine
- Where
- 8 sites in Netherlands
- Volunteers
- 131 people
- Sponsor
- University Medical Center Groningen
Lupus Nephritis, Autoimmune Diseases
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease.
- Conditions
- Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT06375993
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Adicet Therapeutics
ANCA Associated Vasculitis
Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis
This is a prospective observational study to determine the frequency and magnitude of Cytomegalovirus (CMV) reactivation in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) in the acute…
- Trial name
- REACTIVAS (NCT04916704)
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
ANCA Associated Vasculitis (AAV)
PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune condition characterised by inflammation of small blood vessels.
- Trial name
- PANDA-VASC (NCT07258524)
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
ANCA Associated Vasculitis (AAV)
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
The goal of this clinical trial is to learn if avacopan in combination with short-term (4 weeks) reduced-dose glucocorticoid and rituximab works to treat patients with newly-onset ANCA-associated vasculitis.
- Trial name
- ARRIA (NCT06611696)
- Testing
- Avacopan, prednisolone and rituximab, Prednisolone and rituximab
- Where
- 22 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Chiba University
Churg-Strauss Syndrome
Eosinophilic Granulomatosis With Polyangiitis Cohort
EGPA (Eosinophilic Granulomatosis with Polyangiitis, previously Churg-Strauss syndrome) is a rare vasculitis, characterised by asthma, rhinosinusitis and eosinophilia.
- Trial name
- EGPA Cohort (NCT03036670)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Pneumococcal Infection, ANCA-associated Vasculitis
Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis
Descriptive study of the residual anti-pneumococcal immunity in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) who have previously gone through pneumococcal immunization.
- Trial name
- NCT02463539
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
- Conditions
- Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis
- Trial name
- NCT06978738
- Testing
- universal allogeneic anti-CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changzhou No.2 People's Hospital